症例報告: 微細化された浄化フラボノイド分泌物[ダフロン]によるブラディカルディア
Jhennyfer Aline Lima Rodrigues1, Jonathas Pereira das Graças1, Gledson de Oliveira Machado2
1Universidade Estadual de Goiás, Goiás, Brazil.
慢性静脈疾患の患者では,微細化された浄化フラボノイド分 (MPFF) が心拍数を有意に低下させた. この研究は,MPFFが心拍数を弱める可能性を示唆し,その静脈活性効果を心血管調節と関連付けています.
科学分野:
- 薬理学について
- 心血管の生理学
背景:
- フラボノイドは,MPFFのディオスミンとヘスペリディンを含む,慢性静脈疾患に使用されます.
- MPFF (ダフロン 1000 mg) は,抗炎症および抗酸化作用を有する.
さらに関連する動画
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
関連する概念動画
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Dysrhythmias VII: Nursing Management of Dysrhythmias
